Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer

International Journal of Oncology

Volumn 37, Issue 1, 2010, Pages 41-49

  Nagai, Maria Aparecida ^a   Gerhard, Renê ^a   Salaorni, Sibeli ^a   Fregnani, José Humberto Tavares Guerreiro ^b   Nonogaki, Suely ^c   Netto, Mário Mourão ^d   Soares, Fernando Augusto ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

^d A C CAMARGO CANCER CENTER   (Brazil)

Author keywords

3D cell culture; Breast cancer; Immunohistochemistry; Molecular marker; PAR 4; Tissue microarrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 4; APOPTOSIS REGULATORY PROTEIN; PROSTATE APOPTOSIS RESPONSE-4 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER PATIENT; CANCER SURVIVAL; CELL STRUCTURE; CONTROL GROUP; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LOG RANK TEST; MAJOR CLINICAL STUDY; MAMMARY GLAND; MORPHOGENESIS; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; TISSUE MICROARRAY; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; GENETIC ASSOCIATION; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL; TUMOR CELL CULTURE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DOWN-REGULATION; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77953213466     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000651     Document Type: Article

References (44)

1. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
2. Call JA, Eckhardt SG and Camidge DR: Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 9: 1002-1011, 2008.
3. Zhao Y and Rangnekar VM: Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7: 1867-1874, 2008.
4. Sells SF, Han SS, Muthukkumar S, Maddiwar N, Johnstone R, Boghaert E, Gillis D, Liu G, Nair P, Monnig S, Collini P, Mattson MP, Sukhatme VP, Zimmer SG, Wood DP Jr, McRoberts JW, Shi Y and Rangnekar VM: Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol 17: 3823-3832, 1997.
5. Johnstone RW, Tommerup N, Hansen C, Vissing H and Shi Y: Mapping of the human PAR-4 (par-4) gene to chromosome 12q21. Genomics 53: 241-243, 1998.
6. El-Guendy N, Zhao Y, Gurumurthy S, Burikhanov R and Rangnekar VM: Identification of a unique core domain of par-4 sufficient for selective apoptosis induction in cancer cells. Mol Cell Biol 23: 5516-5525, 2003. (Pubitemid 36951320)
7. Sells SF, Wood DP Jr, Joshi-Barve SS, Muthukumar S, Jacob RJ, Crist SA, Humphreys S and Rangnekar VM: Commonality of the gene programs induced by effectors of apoptosis in androgen-dependent and -independent prostate cells. Cell Growth Differ 5: 457-466, 1994. (Pubitemid 24251397)
8. Ranganathan P and Rangnekar VM: Regulation of cancer cell survival by Par-4. Ann NY Acad Sci 1059: 76-85, 2005. (Pubitemid 43211613)
9. Johnstone RW, See RH, Sells SF, Wang J, Muthukkumar S, Englert C, Haber DA, Licht JD, Sugrue SP, Roberts T, Rangnekar VM and Shi Y: A novel repressor, par-4, modulates transcription and growth suppression functions of the Wilms' tumor suppressor WT1. Mol Cell Biol 16: 6945-6956, 1996.
10. Page G, Kögel D, Rangnekar V and Scheidtmann KH: Interaction partners of Dlk/ZIP kinase: co-expression of Dlk/ZIP kinase and Par-4 results in cytoplasmic retention and apoptosis. Oncogene 18: 7265-7273, 1999. (Pubitemid 30032105)
11. Cheema SK, Mishra SK, Rangnekar VM, Tari AM, Kumar R and Lopez-Berestein G: Par-4 transcriptionally regulates Bcl-2 through a WT1-binding site on the bcl-2 promoter. J Biol Chem 278: 19995-20005, 2003.
12. Garcia-Cao I, Lafuente MJ, Criado LM, Diaz-Meco MT, Serrano M and Moscat J: Genetic inactivation of Par4 results in hyperactivation of NF-kappaB and impairment of JNK and p38. EMBO Rep 4: 307-312, 2003. (Pubitemid 36511729)
13. Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH and Rangnekar VM: Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18: 623-631, 1999. (Pubitemid 29080319)
14. Boehrer S, Chow KU, Beske F, Kukoc-Zivojnov N, Puccetti E, Ruthardt M, Baum C, Rangnekar VM, Hoelzer D, Mitrou PS and Weidmann E: In lymphatic cells par-4 sensitizes to apoptosis by down-regulating bcl-2 and promoting disruption of mitochondrial membrane potential and caspase activation. Cancer Res 62: 1768-1775, 2002.
15. Chakraborty M, Qiu SG, Vasudevan KM and Rangnekar VM: Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 61: 7255-7263, 2001. (Pubitemid 32946523)
16. Gurumurthy S, Goswami A, Vasudevan KM and Rangnekar VM: Phosphorylation of Par-4 by protein kinase A is critical for apoptosis. Mol Cell Biol 25: 1146-1161, 2005.
17. Goswami A, Ranganathan P and Rangnekar VM: The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66: 2889-2892, 2006.
18. Goswami A, Burikhanov R, De Thonel A, Fujita N, Goswami M, Zhao Y, Eriksson JE, Tsuruo T and Rangnekar VM: Binding and phosphorylation of par-4 by akt is essential for cancer cell survival. Mol Cell 20: 33-44, 2005.
19. Boghaert ER, Sells SF, Walid AJ, Malone P, Williams NM, Weinstein MH, Strange R and Rangnekar VM: Immunohistochemical analysis of the proapoptotic protein Par-4 in normal rat tissues. Cell Growth Differ 8: 881-890, 1997. (Pubitemid 27355461)
20. Gurumurthy S and Rangnekar VM: Par-4 inducible apoptosis in prostate cancer cells. J Cell Biochem 91: 504-512, 2004.
21. Díaz-Meco MT, Municio MM, Frutos S, Sanchez P, Lozano J, Sanz L and Moscat J: The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C. Cell 86: 777-786, 1996. (Pubitemid 26303446)
22. El Affar B, Luke MP, Gay F, Calvo D, Sui G, Weiss RS, Li E and Shi Y: Targeted ablation of Par-4 reveals a cell type-specific susceptibility to apoptosis-inducing agents. Cancer Res 66: 3456-3462, 2006.
23. Chan SL, Tammariello SP, Estus S and Mattson MP: Prostate apoptosis response-4 mediates trophic factor withdrawal-induced apoptosis of hippocampal neurons: actions prior to mitochondrial dysfunction and caspase activation. J Neurochem 73: 502-512, 1999.
24. Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM and Weidmann E: Deregulated expression of prostate apoptosis response gene-4 in less differentiated lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2: 103-107, 2001.
25. Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH and Rangnekar VM: Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18: 1205-1208, 1999. (Pubitemid 29085993)
26. Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M and Palacios J: Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67: 1927-1934, 2007.
27. Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S, Wood C, Mohiuddin M and Strodel WE: Down-regulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer 122: 63-70, 2008. (Pubitemid 350209979)
28. Gao S, Wang H, Lee P, Melamed J, Li CX, Zhang F, Wu H, Zhou L and Wang Z: Androgen receptor and prostate apoptosis response factor-4 target the c-FLIP gene to determine survival and apoptosis in the prostate gland. J Mol Endocrinol 36: 463-483, 2006. (Pubitemid 43904941)
29. Nagai MA, Fregnani JH, Netto MM, Brentani MM and Soares FA: Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 106: 49-56, 2007.
30. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
31. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M and Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10: 5367-5374, 2004.
32. Diaz LK, Gupta R, Kidwai N, Sneige N and Wiley EL: The use of TMA for interlaboratory validation of FISH testing for detection of HER2 gene amplification in breast cancer. J Histochem Cytochem 52: 501-507, 2004. (Pubitemid 38420384)
33. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007. (Pubitemid 46698581)
34. Debnath J, Muthuswamy SK and Brugge JS: Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268, 2003. (Pubitemid 36677560)
35. García-Cao I, Duran A, Collado M, Carrascosa MJ, Martín-Caballero J, Flores JM, Diaz-Meco MT, Moscat J and Serrano M: Tumour-suppression activity of the proapoptotic regulator Par4. EMBO Rep 6: 577-583, 2005. (Pubitemid 40973968)
36. Fresno Vara JA, Casado E, De Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
37. Sansal I and Sellers WR: The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 22: 2954-2963, 2004. (Pubitemid 41079915)
38. Chung MJ, Jung SH, Lee BJ, Kang MJ and Lee DG: Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathol Int 54: 10-15, 2004.
39. Lin NU and Winer EP: New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res 6: 204-210, 2004.
40. Tokunaga E, Kimura Y, Oki E, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Baba H and Maehara Y: Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 118: 284-289, 2006.
41. Lee GY, Kenny PA, Lee EH and Bissell MJ: Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365, 2007.
42. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK and Brugge JS: The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40, 2002.
43. Green KA and Streuli CH: Apoptosis regulation in the mammary gland. Cell Mol Life Sci 61: 1867-1883, 2004.
44. Muthuswamy SK, Li D, Lelievre S, Bissell MJ and Brugge JS: ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792, 2001. (Pubitemid 32842683)